Voncento

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
13-05-2022
Karakteristik produk Karakteristik produk (SPC)
13-05-2022

Bahan aktif:

Human coagulation factor VIII, human von willebrand factor

Tersedia dari:

CSL Behring GmbH

Kode ATC:

B02BD06

INN (Nama Internasional):

human coagulation factor VIII / human von willebrand factor

Kelompok Terapi:

Blood coagulation factors, von Willebrand factor and coagulation factor VIII in combination, Antihemorrhagics

Area terapi:

Hemophilia A; von Willebrand Diseases

Indikasi Terapi:

Von Willebrand disease (VWD)Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.Haemophilia A (congenital factor-VIII deficiency)Prophylaxis and treatment of bleeding in patients with haemophilia A.

Ringkasan produk:

Revision: 15

Status otorisasi:

Authorised

Tanggal Otorisasi:

2013-08-12

Selebaran informasi

                                41
B. PACKAGE LEAFLET
42
PACKAGE LEAFLET: INFORMATION FOR THE USER
VONCENTO 250 IU FVIII / 600 IU VWF (5 ML SOLVENT) POWDER AND SOLVENT
FOR SOLUTION FOR
INJECTION/INFUSION
VONCENTO 500 IU FVIII / 1200 IU VWF(10 ML SOLVENT) POWDER AND SOLVENT
FOR SOLUTION FOR
INJECTION/INFUSION
VONCENTO 500 IU FVIII / 1200 IU VWF (5 ML SOLVENT) POWDER AND SOLVENT
FOR SOLUTION FOR
INJECTION/INFUSION
VONCENTO 1000 IU FVIII / 2400 IU VWF (10 ML SOLVENT) POWDER AND
SOLVENT FOR SOLUTION FOR
INJECTION/INFUSION
human coagulation factor VIII,
human von Willebrand factor
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have further questions, ask your doctor, your nurse or your
pharmacist.

This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.

If you get any side effects talk to your doctor, nurse or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Voncento is and what it is used for
2.
What you need to know before you use Voncento
3.
How to use Voncento
4.
Possible side effects
5.
How to store Voncento
6.
Contents of the pack and other information
1.
WHAT VONCENTO IS AND WHAT IT IS USED FOR
The product is made from human plasma (the liquid part of the blood)
and contains the active
substances called human coagulation factor VIII (FVIII) and human von
Willebrand factor (VWF).
Voncento is used for all age groups to prevent or to halt bleeding
caused by the lack of VWF in von
Willebrand disease (VWD) and the lack of FVIII in haemophilia A.
Voncento is only used when
treatment with another medicine, desmopressin, is not effective alone
or cannot be given.
VWF and FVIII are involved in blood clotting. Lack of either factor
means that blood does not clot as
quickly as it should so there is an increased tendency to bleed. The
replacemen
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent
for solution for
injection/infusion
Voncento 500 IU FVIII /1200 IU VWF (10 ml solvent) powder and solvent
for solution for
injection/infusion
Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent
for solution for
injection/infusion
Voncento 1000 IU FVIII / 2400 IU VWF (10 ml solvent) powder and
solvent for solution for
injection/infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Voncento 250 IU FVIII / 600 IU VWF powder and solvent for solution for
injection/infusion
One vial of powder contains nominally:
-
250 IU* human coagulation factor VIII** (FVIII).
-
600 IU*** human von Willebrand factor** (VWF).
After reconstitution with the 5 ml water for injections provided, the
solution contains 50 IU/ml of
FVIII and 120 IU/ml of VWF.
Voncento 500 IU FVIII / 1200 IU VWF powder and solvent for solution
for injection/infusion
One vial of powder contains nominally:
-
500 IU* human coagulation factor VIII** (FVIII).
-
1200 IU*** human von Willebrand factor** (VWF).
After reconstitution with the 10 ml water for injections provided, the
solution contains 50 IU/ml of
FVIII and 120 IU/ml of VWF.
Voncento 500 IU FVIII / 1200 IU VWF powder and solvent for solution
for injection/infusion
One vial of powder contains nominally:
-
500 IU* human coagulation factor VIII** (FVIII).
-
1200 IU*** human von Willebrand factor** (VWF).
After reconstitution with the 5 ml water for injections provided, the
solution contains 100 IU/ml of
FVIII and 240 IU/ml of VWF.
Voncento 1000 IU FVIII / 2400 IU VWF powder and solvent for solution
for injection/infusion
One vial of powder contains nominally:
-
1000 IU* human coagulation factor VIII** (FVIII).
-
2400 IU*** human von Willebrand factor** (VWF).
After reconstitution with the 10 ml water for injections provided, the
solution contains 100 IU/ml of
FVIII and 240 IU/ml of VWF.
_________________________________________
* The FVIII poten
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 13-05-2022
Karakteristik produk Karakteristik produk Bulgar 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Bulgar 16-01-2018
Selebaran informasi Selebaran informasi Spanyol 13-05-2022
Karakteristik produk Karakteristik produk Spanyol 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Spanyol 16-01-2018
Selebaran informasi Selebaran informasi Cheska 13-05-2022
Karakteristik produk Karakteristik produk Cheska 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Cheska 16-01-2018
Selebaran informasi Selebaran informasi Dansk 13-05-2022
Karakteristik produk Karakteristik produk Dansk 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Dansk 16-01-2018
Selebaran informasi Selebaran informasi Jerman 13-05-2022
Karakteristik produk Karakteristik produk Jerman 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Jerman 16-01-2018
Selebaran informasi Selebaran informasi Esti 13-05-2022
Karakteristik produk Karakteristik produk Esti 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Esti 16-01-2018
Selebaran informasi Selebaran informasi Yunani 13-05-2022
Karakteristik produk Karakteristik produk Yunani 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Yunani 16-01-2018
Selebaran informasi Selebaran informasi Prancis 13-05-2022
Karakteristik produk Karakteristik produk Prancis 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Prancis 16-01-2018
Selebaran informasi Selebaran informasi Italia 13-05-2022
Karakteristik produk Karakteristik produk Italia 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Italia 16-01-2018
Selebaran informasi Selebaran informasi Latvi 13-05-2022
Karakteristik produk Karakteristik produk Latvi 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Latvi 16-01-2018
Selebaran informasi Selebaran informasi Lituavi 13-05-2022
Karakteristik produk Karakteristik produk Lituavi 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Lituavi 16-01-2018
Selebaran informasi Selebaran informasi Hungaria 13-05-2022
Karakteristik produk Karakteristik produk Hungaria 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Hungaria 16-01-2018
Selebaran informasi Selebaran informasi Malta 13-05-2022
Karakteristik produk Karakteristik produk Malta 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Malta 16-01-2018
Selebaran informasi Selebaran informasi Belanda 13-05-2022
Karakteristik produk Karakteristik produk Belanda 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Belanda 16-01-2018
Selebaran informasi Selebaran informasi Polski 13-05-2022
Karakteristik produk Karakteristik produk Polski 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Polski 16-01-2018
Selebaran informasi Selebaran informasi Portugis 13-05-2022
Karakteristik produk Karakteristik produk Portugis 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Portugis 16-01-2018
Selebaran informasi Selebaran informasi Rumania 13-05-2022
Karakteristik produk Karakteristik produk Rumania 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Rumania 16-01-2018
Selebaran informasi Selebaran informasi Slovak 13-05-2022
Karakteristik produk Karakteristik produk Slovak 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Slovak 16-01-2018
Selebaran informasi Selebaran informasi Sloven 13-05-2022
Karakteristik produk Karakteristik produk Sloven 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Sloven 16-01-2018
Selebaran informasi Selebaran informasi Suomi 13-05-2022
Karakteristik produk Karakteristik produk Suomi 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Suomi 16-01-2018
Selebaran informasi Selebaran informasi Swedia 13-05-2022
Karakteristik produk Karakteristik produk Swedia 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Swedia 16-01-2018
Selebaran informasi Selebaran informasi Norwegia 13-05-2022
Karakteristik produk Karakteristik produk Norwegia 13-05-2022
Selebaran informasi Selebaran informasi Islandia 13-05-2022
Karakteristik produk Karakteristik produk Islandia 13-05-2022
Selebaran informasi Selebaran informasi Kroasia 13-05-2022
Karakteristik produk Karakteristik produk Kroasia 13-05-2022
Laporan Penilaian publik Laporan Penilaian publik Kroasia 16-01-2018

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen